Core Viewpoint - The company, Hualan Biological Engineering Inc., has released its first quarter report for 2025, ensuring the accuracy and completeness of the financial information disclosed, with no significant omissions or misleading statements [1][2]. Financial Data Summary - The first quarter report has not been audited [3][7]. - The company does not require retrospective adjustments or restatements of previous accounting data [3]. - Non-recurring gains and losses include a refund of handling fees [3]. - The company confirms that there are no instances of classifying non-recurring gains and losses as recurring [3]. Shareholder Information - As of the reporting period, the total number of ordinary shareholders is not disclosed, but the company holds 6,027,467 shares in a repurchase account, representing 1.00% of total shares, ranking fifth among the top ten shareholders [5].

前十大流通股东累计持有： 6373.06万股，累计占流通股比： 44.97%，较上期变化： -66.00万 股。 一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.0551 | 0.0643 | -14.31 | 0.2349 | | 每股净资产（元） | 10.06 | 10.51 | -4.28 | 13.99 | | 每股公积金(元) | 4.87 | 4.87 | 0 | 7.74 | | 每股未分配利润(元) | 3.87 | 4.17 | -7.19 | 4.75 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 0.24 | 0.34 | -29.41 | 1.45 | | 净利润(亿元) | 0.33 | 0.39 | -15.38 | 0.94 | | 净资产收益率(%) | 0.54 | 0.61 | -11.48 | 1.70 | 数据四舍五入，查看更多财务数据> ...

Financial Performance - The company's revenue for Q1 2025 was ¥24,282,534.72, representing a decrease of 29.05% compared to ¥34,222,695.90 in the same period last year[5] - Net profit attributable to shareholders was ¥32,777,072.14, down 15.06% from ¥38,589,463.38 year-on-year[5] - Total operating revenue decreased to ¥24,282,534.72 from ¥34,222,695.90, representing a decline of approximately 29.1% year-over-year[17] - Net profit for the period was ¥32,777,072.14, down from ¥38,589,463.38, reflecting a decrease of approximately 15.1% year-over-year[18] - Basic earnings per share decreased by 14.31% to ¥0.0551 from ¥0.0643 in the same period last year[5] - Basic earnings per share decreased to ¥0.0551 from ¥0.0643, a decline of about 14.3% year-over-year[19] - Other income decreased to ¥2,558,547.64 from ¥3,545,030.98, a decline of about 27.9% year-over-year[18] Cash Flow - The net cash flow from operating activities was negative at -¥2,587,625.81, a decline of 102.68% compared to ¥96,429,081.13 in the previous year[5] - Cash inflow from operating activities totaled $224.24 million, a decrease from $494.88 million year-over-year[22] - Cash outflow related to operating activities was $226.83 million, compared to $398.45 million in the previous period[22] - Cash received from sales of goods and services was ¥214,904,356.36, down from ¥487,216,616.88, a decline of about 55.8% year-over-year[21] - Cash flow from financing activities showed a net outflow of -$30.66 million, compared to -$1.52 million in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,443,158,707.85, a decrease of 1.06% from ¥7,523,255,843.58 at the end of the previous year[5] - The company's cash and cash equivalents decreased to CNY 490,186,996.72 from CNY 623,035,019.91, reflecting a decline of approximately 21.3%[14] - Accounts receivable decreased to CNY 1,276,094,419.94 from CNY 1,437,459,795.12, indicating a reduction of about 11.2%[14] - The company’s long-term assets decreased to CNY 2,384,676,612.06 from CNY 2,546,736,316.68, a decline of approximately 6.4%[15] - Total liabilities decreased to ¥1,395,440,931.16 from ¥1,510,111,321.68, a reduction of approximately 7.6% year-over-year[16] - Total equity increased to ¥6,047,717,776.69 from ¥6,013,144,521.90, reflecting a growth of about 0.6% year-over-year[16] Expenses - Management expenses decreased by 37.18% to ¥7,947,905.52, mainly due to reduced equity incentive costs and employee benefits[8] - Research and development expenses increased to ¥22,115,565.91 from ¥19,022,504.10, an increase of approximately 16.4% year-over-year[18] - The company reported a 100.92% increase in financial expenses to ¥32,632.44, attributed to a decrease in interest income[8] Shareholder Information - The company has a total of 6,027,467 shares held in a repurchase account, accounting for 1.00% of total shares, ranking it as the 5th largest shareholder[12] - The company has a significant shareholder, CYBER CREATOR LIMITED, holding 8.98% of shares, indicating a strategic partnership[12] Government Support - The company received government subsidies amounting to ¥2,558,543.66, which are closely related to its normal business operations[6] Other Financial Metrics - The weighted average return on net assets was 0.54%, down from 0.61% in the previous year[5] - Deferred income tax liabilities decreased to ¥17,126,331.11 from ¥18,800,579.72, a reduction of approximately 8.9% year-over-year[16] - The impact of exchange rate changes on cash and cash equivalents was $55,928, contrasting with a negative impact of -$45,054 in the previous period[22]

证券代码：301207 证券简称：华兰疫苗 公告编号：2025-024 华兰生物疫苗股份有限公司 2024年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东大会未出现否决议案的情形。 2.本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、本次股东大会的召开时间： 现场会议召开时间为：2025 年 4 月 25 日下午 13:00 网络投票时间：2025 年 4 月 25 日。其中通过深圳证券交易所交易系统进行网 络投票的具体时间为 2025 年 4 月 25 日上午 9:15—9:25,9:30—11:30 和下午 13:00— 15:00；通过深圳证券交易所互联网投票的具体时间为 2025 年 4 月 25 日 9:15 至 15:00 期间的任意时间。 2、会议召开地点：华兰生物疫苗股份有限公司（以下简称"公司"）办公楼会议 室 3、召集人：公司董事会 4、会议方式：现场投票、网络投票相结合的方式 5、现场会议主持人：董事长安康先生 6、本次股东大会的会议召集、召开程序符合有关法律、法 ...

关于 华兰生物疫苗股份有限公司 安徽承义律师事务所 召开 2024 年度股东大会的 法律意见书 安徽承义律师事务所 中国.合肥市政务区怀宁路 200 号栢悦中心 5 楼 邮编: 230022 电话（Tel）: （86-551）65609815 传真（Fax）: （86-551）65608051 网址（Website）: www.chengyi-law.com 电子信箱（E-mail）：chengyilawyer@163.com 安徽承义律师事务所 关于华兰生物疫苗股份有限公司 召开 2024 年度股东大会的法律意见书 （2025）承义法字第 00070 号 致：华兰生物疫苗股份有限公司 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东 会规则》等法律法规和其他规范性文件的要求，安徽承义律师事务所接受华兰生 物疫苗股份有限公司（以下简称"公司"）的委托，指派束晓俊、万晓宇律师（以 下简称"本律师"）就公司召开 2024 年度股东大会（以下简称"本次股东大会"） 出具法律意见书。 一、本次股东大会召集人资格和召集、召开的程序 经核查，本次股东大会是由公司第二届董事会召集，公司已于 2025 年 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301207 证券简称：华兰疫苗公告编号：2025-022 华兰生物疫苗股份有限公司 关于召开2024年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 华兰生物疫苗股份有限公司（以下简称"公司"）已于2025年3月29日在《证券时报》、《中国证券 报》、《上海证券报》及巨潮资讯网（www.cninfo.com.cn）披露了《关于召开2024年度股东大会的通 知》（公告编号：2025-020）。本次股东大会采取现场投票和网络投票相结合的表决方式召开，根据有 关规定，现将股东大会的相关事项再次提示如下： 一、召开会议的基本情况 1、股东大会届次：2024年度股东大会； 2、股东大会召集人：公司董事会； 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行政法规、部门规章、规范性 文件和公司章程的规定。 4、会议召开方式：现场投票+网络投票 （1）现场投票：股东本人出席现场会议或者通过授权委托书（附件二）委托他人出席现场会议； （2）网络投票：本次股东大会通过深圳证券交 ...

华兰生物疫苗股份有限公司董事会 华兰生物疫苗股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，公司董事会收到张守涛先生的通知，其已按相关规定参加了深圳证券交 易所举办的上市公司独立董事任前培训（线上），并取得了由深圳证券交易所创业 企业培训中心颁发的《上市公司独立董事培训证明》。 特此公告。 证券代码：301207 证券简称：华兰疫苗 公告编号：2025-023 关于独立董事候选人取得独立董事资格证书的公告 华兰生物疫苗股份有限公司（以下简称"公司"）于 2025 年 3 月 28 日召开第二 届董事会第十三次会议，审议通过了《关于补选第二届董事会独立董事的议案》， 董事会同意提名张守涛先生为公司第二届董事会独立董事候选人，任期自股东大会 审议通过之日起至第二届董事会任期届满之日止。 截至公司股东大会通知发出之日，张守涛先生尚未取得深圳证券交易所认可的 独立董事资格证书，根据《上市公司独立董事管理办法》《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规的相关要求，张 守涛先生需报名参加独立董事任前培训，并承 ...

证券代码：301207 证券简称：华兰疫苗 公告编号：2025-022 华兰生物疫苗股份有限公司 关于召开2024年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 华兰生物疫苗股份有限公司（以下简称"公司"）已于2025年3月29日在《证券 时报》、《中国证券报》、《上海证券报》及巨潮资讯网（www.cninfo.com.cn）披 露了《关于召开2024年度股东大会的通知》（公告编号：2025-020）。本次股东大会 采取现场投票和网络投票相结合的表决方式召开，根据有关规定，现将股东大会的 相关事项再次提示如下： 一、召开会议的基本情况 1、股东大会届次：2024年度股东大会； 2、股东大会召集人：公司董事会； 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行政法 规、部门规章、规范性文件和公司章程的规定。 7、出席对象： 4、会议召开方式：现场投票+网络投票 （1）现场投票：股东本人出席现场会议或者通过授权委托书（附件二）委托他 人出席现场会议； （2）网络投票：本次股东大会通过深圳证券交易所交易系统和互联网投票系统 ...

华泰联合证券有限责任公司 关于华兰生物疫苗股份有限公司 2024 年度跟踪报告 | 保荐人名称：华泰联合证券有限责任公司 | 被保荐公司简称：华兰疫苗 | | --- | --- | | 保荐代表人姓名：贾鹏 | 联系电话：010-56839300 | | 保荐代表人姓名：刘晓宁 | 联系电话：010-56839300 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但 不限于防止关联方占用公司资源的制度、募集 | | | | 是 | | 资金管理制度、内控制度、内部审计制度、关 | | | 联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月一次 | | （2）公司募集资金项目进展是否与信息披露 | 是 | | 文件一致 | | | 4 ...

Core Viewpoint - The domestic largest influenza vaccine manufacturer, Hualan Biological Engineering, has reported significant declines in revenue and net profit due to price wars and low vaccination rates, marking the lowest figures in five years [1] Group 1: Financial Performance - In 2024, Hualan Biological achieved an operating income of 1.128 billion yuan, a year-on-year decrease of 53.21% [1] - The net profit for the same year was 206 million yuan, down 76.10% year-on-year [1] - The gross profit margin for influenza vaccines was 81.84%, reflecting a decline of 6.45% compared to the previous year [2] - The net cash flow from operating activities was 468 million yuan, a decrease of 47.29% year-on-year, indicating weakened cash flow due to reduced sales collections [2] Group 2: Market Dynamics - The influenza vaccine market is experiencing intense price competition, with Hualan's main product prices reduced by approximately 30%, directly impacting revenue and gross margins [1][2] - The vaccination rate in China remains low at around 3%, significantly below global levels, with only about 60% of the total approved vaccine quantity actually administered [2] - The market demand for influenza vaccines has shown increased volatility, with a reported waste rate of approximately 40% in 2024, doubling from 20% in 2018 [2] Group 3: Production and Sales Trends - In 2024, the number of batches for the trivalent influenza vaccine increased from 6 to 11, a year-on-year growth of 83.33%, while the quadrivalent vaccine batches decreased from 88 to 67, a decline of 23.86% [3] - The sales volume of vaccines was 14.2419 million doses, down 26.58% year-on-year, and the production volume was 21.1131 million doses, down 16.74% year-on-year [3] - The HPV vaccine market has also shifted from a previous shortage to a more balanced supply-demand situation, with significant increases in production capacity [3][4] Group 4: Future Outlook - Despite current market pressures, Hualan Biological remains optimistic about the domestic influenza vaccine market, anticipating growth potential driven by government policies and increased public awareness of vaccination [4] - The company faces the challenge of navigating through the dual pressures of price wars and low vaccination rates to achieve market breakthroughs [4]